(CLDN18.2+CD19) targeted Chimeric Antigen Receptor T Cells (CART) Therapy for gastric cancer
Latest Information Update: 03 Oct 2019
Price :
$35 *
At a glance
- Drugs Anti-CLDN18.2 anti-CD19 chimeric antigen receptor cell therapy Innovative Cellular Therapeutics (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 03 Oct 2019 New trial record